Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010, Article ID 424786, 6 pages
http://dx.doi.org/10.1155/2010/424786
Review Article

An Update in Management of Noncutaneous T-Cell Lymphomas

Division of Haematology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong

Received 31 August 2010; Accepted 28 October 2010

Academic Editor: F. M. Foss

Copyright © 2010 Y. Y. Hwang and R. H. S. Liang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Mature T-cell and NK-cell neoplasms,” in WHO Classification of Tumours and Haematopoietic and Lymphoid Tissues, S. H. Swerdlow, E. Campo, N. L. Harris et al., Eds., pp. 270–319, International Agency for Research on Cancer, Lyon, France, 2008.
  2. C. Gisselbrecht, P. Gaulard, and P. Gaulard, “Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA),” Blood, vol. 92, no. 1, pp. 76–82, 1998. View at Google Scholar · View at Scopus
  3. A.-L. Cheng, Y.-C. Chen, and Y.-C. Chen, “Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades—should peripheral T-cell lymphoma be considered separately?” Journal of Clinical Oncology, vol. 7, no. 6, pp. 725–731, 1989. View at Google Scholar · View at Scopus
  4. A. López-Guillermo, J. Cid, and J. Cid, “Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification,” Annals of Oncology, vol. 9, no. 8, pp. 849–855, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Mourad, N. Mounier, and N. Mounier, “Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials,” Blood, vol. 111, no. 9, pp. 4463–4470, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. S. Ascani, P. L. Zinzani, and P. L. Zinzani, “Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification,” Annals of Oncology, vol. 8, no. 6, pp. 583–592, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Vose, M. Neumann, and M. E. Harris, “International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes international T-cell lymphoma project,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4124–4130, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. R. D. Gascoyne, P. Aoun, and P. Aoun, “Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma,” Blood, vol. 93, no. 11, pp. 3913–3921, 1999. View at Google Scholar · View at Scopus
  9. R. L. Ten Berge, J. J. Oudejans, and J. J. Oudejans, “ALK expression in extranodal anaplastic large cell lymphoma layouts systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination,” Journal of Clinical Pathology, vol. 53, no. 6, pp. 445–450, 2000. View at Publisher · View at Google Scholar
  10. L. De Leval, C. Gisselbrecht, and P. Gaulard, “Advances in the understanding and management of angioimmunoblastic T-cell lymphoma,” British Journal of Haematology, vol. 148, no. 5, pp. 673–689, 2010. View at Publisher · View at Google Scholar · View at PubMed
  11. A. Gallamini, C. Stelitano, and C. Stelitano, “Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study,” Blood, vol. 103, no. 7, pp. 2474–2479, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. J. O. Armitage, J. P. Greer, and J. P. Greer, “Peripheral T-cell lymphoma,” Cancer, vol. 63, no. 1, pp. 158–163, 1989. View at Google Scholar · View at Scopus
  13. T. Rüdiger, D. D. Weisenburger, and D. D. Weisenburger, “Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project,” Annals of Oncology, vol. 13, no. 1, pp. 140–149, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Schmitz, L. Trumper, M. Ziepert et al., “Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL),” Blood. In press.
  15. M. P. Escalón, N. S. Liu, Y. Yang, M. Hess, P. L. Walker, T. L. Smith, and N. H. Dang, “Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center Experience,” Cancer, vol. 103, no. 10, pp. 2091–2098, 2005. View at Publisher · View at Google Scholar · View at PubMed
  16. H. Tilly, E. Lepage, and E. Lepage, “Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma,” Blood, vol. 102, no. 13, pp. 4284–4289, 2003. View at Publisher · View at Google Scholar · View at PubMed
  17. N. Mounier, C. Gisselbrecht, and C. Gisselbrecht, “All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA),” Annals of Oncology, vol. 15, no. 12, pp. 1790–1797, 2004. View at Publisher · View at Google Scholar · View at PubMed
  18. M. Nickelsen, M. Ziepert, and M. Ziepert, “High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL),” Annals of Oncology, vol. 20, no. 12, pp. 1977–1984, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. J. Rodríguez, E. Conde, and E. Conde, “The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience,” Annals of Oncology, vol. 18, no. 4, pp. 652–657, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. J. Rodríguez, E. Conde, and E. Conde, “Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo Study Group,” European Journal of Haematology, vol. 79, no. 1, pp. 32–38, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. P. Reimer, T. Rüdiger, and T. Rüdiger, “Autologous stem-cell transplantation as first-line therapy in peripheral t-cell lymphomas: results of a prospective multicenter study,” Journal of Clinical Oncology, vol. 27, no. 1, pp. 106–113, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. P. Corradini, C. Tarella, and C. Tarella, “Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation,” Leukemia, vol. 20, no. 9, pp. 1533–1538, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. A. Gallamini, F. Zaja, and F. Zaja, “Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial,” Blood, vol. 110, no. 7, pp. 2316–2323, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. P. L. Zinzani, F. Venturini, and F. Venturini, “Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome,” Annals of Oncology, vol. 21, no. 4, pp. 860–863, 2009. View at Publisher · View at Google Scholar · View at PubMed
  25. S. Sallah, J. Y. Wan, and N. P. Nguyen, “Treatment of refractory T-cell malignancies using gemcitabine,” British Journal of Haematology, vol. 113, no. 1, pp. 185–187, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. J. G. Kim, S. K. Sohn, and S. K. Sohn, “CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas,” Cancer Chemotherapy and Pharmacology, vol. 58, no. 1, pp. 35–39, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. H.-T. Arkenau, G. Chong, and G. Chong, “Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience,” Haematologica, vol. 92, no. 2, pp. 271–272, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. E. S. Wang, O. O'Connor, Y. She, A. D. Zelenetz, F. M. Sirotnak, and M. A. S. Moore, “Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression,” Leukemia and Lymphoma, vol. 44, no. 6, pp. 1027–1035, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. L. E. Toner, R. Vrhovac, and R. Vrhovac, “The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-hodgkin's lymphoma,” Clinical Cancer Research, vol. 12, no. 3, pp. 924–932, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. O. A. O'Connor, S. Horwitz, and S. Horwitz, “Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies,” Journal of Clinical Oncology, vol. 27, no. 26, pp. 4357–4364, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. O. O’Connor, B. Pro, and L. L. Pinter-Brown, “Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL),” Journal of Clinical Oncology, vol. 27, no. 15, supplement, 2009, abstract no. 8561. View at Google Scholar
  32. R. L. Piekarz, “Phase II trial of single agent romidepsin in relapsed peripheral T cell lymphoma,” in Proceedings of the 50th Annual American Society of Hematology, 2009, abstract no. 14157.
  33. P. B. Johnston, S. M. Ansell, J. P. Colgan et al., “mTOR inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with Everolimus (RAD001),” in Proceedings of the ASH Annual Meeting, p. 110, 2007, abstract no. 2555.
  34. N. L. Bartlett, A. Younes, and A. Younes, “A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies,” Blood, vol. 111, no. 4, pp. 1848–1854, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. F. D'Amore, J. Radford, and J. Radford, “Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma,” British Journal of Haematology, vol. 150, no. 5, pp. 565–573, 2010. View at Publisher · View at Google Scholar · View at PubMed
  36. J. Lee, C. Suh, and C. Suh, “Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma,” Annals of Oncology, vol. 19, no. 12, pp. 2079–2083, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. S. Horwitz, D. Mulford, H. Paul et al., “Clofarabine is active in peripheral T-cell lymphomas: results of the phase I portion of a phase I/II study,” Annals of Oncology, vol. 19, supplement 4, p. iv157, 2008, abstract no. 244. View at Google Scholar
  38. G. S. Dueck, N. Chua, A. Prasad et al., “Activity of lenalidomide in a phase II trial for T-cell lymphoma: a report on the first 24 cases,” Journal of Clinical Oncology, vol. 27, no. 15, supplement, 2009, abstract no. 8524. View at Google Scholar
  39. C. Kyriakou, C. Canals, and C. Canals, “Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European Group for Blood and Marrow Transplantation,” Journal of Clinical Oncology, vol. 27, no. 24, pp. 3951–3958, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. S. Le Gouill, N. Milpied, and N. Milpied, “Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire,” Journal of Clinical Oncology, vol. 26, no. 14, pp. 2264–2271, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. P. Corradini, A. Dodero, and A. Dodero, “Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells,” Journal of Clinical Oncology, vol. 22, no. 11, pp. 2172–2176, 2004. View at Publisher · View at Google Scholar · View at PubMed
  42. A. R. Shustov, T. A. Gooley, B. M. Sandmaier et al., “Allogeneic haematopoietic cell transplantation after non-myeloablative conditioning in patients with T-cell and natural killer-cell lymphoma,” British Journal of Haematology, vol. 150, pp. 170–178, 2010. View at Google Scholar